Novel FTY720-based compounds stimulate neurotrophin expression and phosphatase activity in dopaminergic cells

Javier Vargas-Medrano, Sesha Krishnamachari, Ernesto Villanueva, Wesley H. Godfrey, Haiyan Lou, Ramesh Chinnasamy, Jeffrey B. Arterburn, Ruth G. Perez

Research output: Contribution to journalArticlepeer-review

27 Scopus citations

Abstract

α-Synuclein is a chaperone-like protein implicated in Parkinsons disease (PD). Among α-synucleins normal functions is an ability to bind to and stimulate the activity of the protein phosphatase 2A (PP2A) catalytic subunit in vitro and in vivo. PP2A activity is impaired in PD and in dementia with Lewy Bodies in brain regions harboring α-synuclein aggregates. Using PP2A as the readout, we measured PP2A activity in response to α-synuclein, ceramides, and FTY720, and then on the basis of those results, we created new FTY720 compounds. We then measured the effects of those compounds in dopaminergic cells. In addition to stimulating PP2A, all three compounds stimulated the expression of brain derived neurotrophic factor and protected MN9D cells against tumor-necrosis-factor-α-associated cell death. FTY720-C2 appears to be more potent while FTY720-Mitoxy targets mitochondria. Importantly, FTY720 is already FDA approved for treating multiple sclerosis and is used clinically worldwide. Our findings suggest that FTY720 and our new FTY720-based compounds have considerable potential for treating synucleinopathies such as PD.

Original languageEnglish (US)
Pages (from-to)782-786
Number of pages5
JournalACS Medicinal Chemistry Letters
Volume5
Issue number7
DOIs
StatePublished - Jul 10 2014

Keywords

  • BDNF
  • PP2A
  • Parkinsons
  • ceramides
  • synucleinopathy
  • triphenylphosphonium
  • α-Synuclein

Fingerprint Dive into the research topics of 'Novel FTY720-based compounds stimulate neurotrophin expression and phosphatase activity in dopaminergic cells'. Together they form a unique fingerprint.

Cite this